公开(公告)号：US20180200360A1

公开(公告)日：2018-07-19

申请号：US15742249

申请日：2016-07-07

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes LANGEDIJK ,  Dirk André Emmy ROYMANS

IPC分类号： A61K39/155 ,  C07K14/005 ,  A61P31/14

CPC分类号： A61K39/155 ,  A61K39/12 ,  A61P31/14 ,  C07K14/005 ,  C07K2319/00 ,  C12N2760/18522 ,  C12N2760/18534

摘要： Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

公开(公告)号：US20230310573A1

公开(公告)日：2023-10-05

申请号：US17995158

申请日：2021-04-01

申请人： Janssen Vaccines & Prevention B.V.

发明人： Tina RITSCHEL ,  Richard VOORZAAT ,  Lucy RUTTEN ,  Mandy Antonia Catharina JONGENEELEN ,  Tim Hugo Maria JONCKERS ,  Dirk André Emmy ROYMANS ,  Johannes Petrus Maria LANGEDIJK

IPC分类号： A61K39/145 ,  A61P31/12

CPC分类号： A61K39/145 ,  A61P31/12 ,  A61K2039/545

摘要： The present invention relates to vaccine composition comprising an immunologically effective amount of a viral fusion protein antigen, such as an RSV pre-fusion F protein, and a stabilizing amount of an antiviral compound, and to methods for preparing such vaccine compositions.

公开(公告)号：US20220125912A1

公开(公告)日：2022-04-28

申请号：US17572097

申请日：2022-01-10

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes Petrus Maria LANGEDIJK ,  Dirk André Emmy ROYMANS

IPC分类号： A61K39/155 ,  A61K39/12 ,  A61P31/14 ,  C07K14/005

摘要： Compositions including a recombinant respiratory syncytial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.

公开(公告)号：US20200061183A1

公开(公告)日：2020-02-27

申请号：US16589601

申请日：2019-10-01

申请人： Janssen Vaccines & Prevention B.V.

发明人： Johannes Petrus Maria LANGEDIJK ,  Dirk André Emmy ROYMANS

IPC分类号： A61K39/155 ,  C07K14/005 ,  A61P31/14 ,  A61K39/12

摘要： Compositions including a recombinant respiratory syncitial virus (RSV) Fusion (F) polypeptide that is stabilized in the pre-fusion conformation are described. The RSV F polypeptide includes at least one mutation as compared to a wild type RSV F polypeptide and the at least one mutation is a) a mutation of the amino acid aspartic acid (D) on position 486, b) a mutation of the amino acid aspartic acid (D) on position 489, or c) a mutation of the amino acid serine (S) on position 398 and/or the amino acid lysine (K) on position 394. Compositions including an isolated nucleic acid molecule encoding the stable RSV F polypeptides are also described.